Infinity Pharmaceuticals, Inc. – NASDAQ:INFI
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Infinity Pharmaceuticals stock price monthly change
-80.15%
month
Infinity Pharmaceuticals stock price quarterly change
-92.31%
quarter
Infinity Pharmaceuticals stock price yearly change
-98.66%
year
Infinity Pharmaceuticals key metrics
Market Cap | 726.08K |
Enterprise value | N/A |
P/E | -0.29 |
EV/Sales | -12.89 |
EV/EBITDA | 0.69 |
Price/Sales | 5.55 |
Price/Book | -1.27 |
PEG ratio | -0.01 |
EPS | -0.44 |
Revenue | 2.56M |
EBITDA | -41.72M |
Income | -39.90M |
Revenue Q/Q | -15.01% |
Revenue Y/Y | 15.87% |
Profit margin | -1870.85% |
Oper. margin | -1871.49% |
Gross margin | 39.7% |
EBIT margin | -1871.49% |
EBITDA margin | -1624.13% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeInfinity Pharmaceuticals stock price history
Infinity Pharmaceuticals stock forecast
Infinity Pharmaceuticals financial statements
| Sep 2022 | 712K | -10.55M | -1482.16% |
|---|---|---|---|
| Dec 2022 | 543K | -8.77M | -1615.29% |
| Mar 2023 | 731K | -10.62M | -1453.9% |
| Jun 2023 | 583K | -9.95M | -1707.72% |
| Sep 2022 | 51591000 | 62.46M | 121.08% |
|---|---|---|---|
| Dec 2022 | 42151000 | 61.20M | 145.2% |
| Mar 2023 | 29951000 | 58.27M | 194.56% |
| Jun 2023 | 21232000 | 58.63M | 276.18% |
| Sep 2022 | -9.40M | 10.73M | 14K |
|---|---|---|---|
| Dec 2022 | -8.9M | 55K | 31K |
| Mar 2023 | -12.57M | 0 | 0 |
| Jun 2023 | -8.00M | 0 | 0 |
Infinity Pharmaceuticals alternative data
| Aug 2023 | 30 |
|---|---|
| Sep 2023 | 30 |
| Oct 2023 | 30 |
| Nov 2023 | 30 |
| Dec 2023 | 30 |
| Jan 2024 | 30 |
| Feb 2024 | 30 |
| Mar 2024 | 30 |
| Apr 2024 | 30 |
| May 2024 | 30 |
| Jun 2024 | 30 |
| Jul 2024 | 30 |
Infinity Pharmaceuticals other data
5.36%
-22.68%
of INFI is owned by hedge funds
30
-33
4.78M
-20.28M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Sep 2023 | 0 | 410196 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | PERKINS ADELENE Q director | Common Stock | 410,196 | $0.07 | $28,714 | ||
Option | PERKINS ADELENE Q director | Common Stock | 768,133 | N/A | N/A | ||
Option | PERKINS ADELENE Q director | Restricted Stock Unit | 768,133 | N/A | N/A | ||
Option | PELUSO STEPHANE director: Chief Scientific Offi.. | Restricted Stock Unit | 50,000 | N/A | N/A | ||
Sale | PELUSO STEPHANE director: Chief Scientific Offi.. | Common Stock | 14,994 | $0.66 | $9,926 | ||
Option | PELUSO STEPHANE officer: Chief Scientific Officer | Common Stock | 50,000 | N/A | N/A | ||
Option | SELBY NORMAN C director | Common Stock | 5,000 | $0.92 | $4,600 | ||
Option | SELBY NORMAN C director | Stock Option (right to buy) | 5,000 | $0.92 | $4,600 | ||
Sale | BVF PARTNERS L P/IL 10 percent owner | Common Stock, $0.001 par value | 2,260,085 | $5.37 | $12,134,396 | ||
Sale | BVF PARTNERS L P/IL 10 percent owner | Common Stock, $0.001 par value | 2,260,085 | $5.37 | $12,134,396 |
| Patent |
|---|
Application Filling date: 14 Sep 2021 Issue date: 4 Aug 2022 |
Application SOLID FORMS OF ISOQUINOLINONES, AND PROCESS OF MAKING, COMPOSITION COMPRISING, AND METHODS OF USING THE SAME Filling date: 18 Jan 2022 Issue date: 5 May 2022 |
Application Filling date: 2 Aug 2021 Issue date: 28 Apr 2022 |
Grant Utility: Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same Filling date: 20 Nov 2018 Issue date: 15 Feb 2022 |
Grant Utility: Combination therapies Filling date: 23 Jun 2017 Issue date: 19 Oct 2021 |
Application Filling date: 28 Sep 2020 Issue date: 9 Sep 2021 |
Grant Utility: Combination therapies Filling date: 4 May 2017 Issue date: 7 Sep 2021 |
Grant Utility: Cyclopamine analogs Filling date: 24 Jul 2019 Issue date: 18 May 2021 |
Grant Filling date: 1 Mar 2019 Issue date: 9 Mar 2021 |
Application Filling date: 14 Apr 2020 Issue date: 4 Mar 2021 |
| Quarter | Transcript |
|---|---|
| Q3 2022 14 Nov 2022 | Q3 2022 Earnings Call Transcript |
| Q2 2022 9 Aug 2022 | Q2 2022 Earnings Call Transcript |
| Q1 2022 3 May 2022 | Q1 2022 Earnings Call Transcript |
| Q4 2021 29 Mar 2022 | Q4 2021 Earnings Call Transcript |
-
When is Infinity Pharmaceuticals's next earnings date?
Unfortunately, Infinity Pharmaceuticals's (INFI) next earnings date is currently unknown.
-
Does Infinity Pharmaceuticals pay dividends?
No, Infinity Pharmaceuticals does not pay dividends.
-
How much money does Infinity Pharmaceuticals make?
Infinity Pharmaceuticals has a market capitalization of 726.08K and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 39.56% to 2.59M US dollars.
-
What is Infinity Pharmaceuticals's stock symbol?
Infinity Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "INFI".
-
What is Infinity Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Infinity Pharmaceuticals?
Shares of Infinity Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Infinity Pharmaceuticals's key executives?
Infinity Pharmaceuticals's management team includes the following people:
- Ms. Adelene Q. Perkins Chairman & Chief Executive Officer(age: 65, pay: $1,150,000)
- Dr. Lawrence E. Bloch Pres & Treasurer(age: 59, pay: $742,450)
- Mr. Seth A. Tasker Senior Vice President, Chief Bus. Officer & Sec.(age: 46, pay: $549,610)
-
How many employees does Infinity Pharmaceuticals have?
As Jul 2024, Infinity Pharmaceuticals employs 30 workers.
-
When Infinity Pharmaceuticals went public?
Infinity Pharmaceuticals, Inc. is publicly traded company for more then 25 years since IPO on 28 Jul 2000.
-
What is Infinity Pharmaceuticals's official website?
The official website for Infinity Pharmaceuticals is infi.com.
-
Where are Infinity Pharmaceuticals's headquarters?
Infinity Pharmaceuticals is headquartered at 1100 Massachusetts Avenue, Cambridge, MA.
-
How can i contact Infinity Pharmaceuticals?
Infinity Pharmaceuticals's mailing address is 1100 Massachusetts Avenue, Cambridge, MA and company can be reached via phone at +61 74531000.
Infinity Pharmaceuticals company profile:
Infinity Pharmaceuticals, Inc.
infi.comExchange:
NASDAQ
Full time employees:
30
Industry:
Biotechnology
Sector:
Healthcare
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.
1100 Massachusetts Avenue
Cambridge, MA 02138
Cambridge, MA 02138
CIK: 0001113148
ISIN: US45665G3039
CUSIP: 45665G303
